[Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome]

Rev Med Interne. 2011 May;32(5):e66-8. doi: 10.1016/j.revmed.2010.06.003. Epub 2010 Jul 14.
[Article in French]

Abstract

We report a 49-year-old man suffering from chronic hypereosinophilia whose biological tests revealed a gene rearrangement between FIP1L1 and PDGFRA as well as a T-cell clonality. After 1 year of therapy with imatinib mesylate (100 mg daily), the patient was clinically asymptomatic, the fusion transcript was undetectable using RTQ-PCR and no lymphoproliferative disorders occurred. This unique combination raises the question of the physiopathology of such a grey zone hypereosinophilia and their management.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Chronic Disease
  • Gene Rearrangement, T-Lymphocyte / genetics
  • Genetic Testing
  • Humans
  • Hypereosinophilic Syndrome / drug therapy
  • Hypereosinophilic Syndrome / genetics*
  • Hypereosinophilic Syndrome / pathology*
  • Imatinib Mesylate
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Oncogene Proteins, Fusion / genetics*
  • Piperazines / therapeutic use
  • Pyrimidines / therapeutic use
  • Receptor, Platelet-Derived Growth Factor alpha / genetics*
  • T-Lymphocytes / pathology*
  • Treatment Outcome
  • mRNA Cleavage and Polyadenylation Factors / genetics*

Substances

  • Antineoplastic Agents
  • Benzamides
  • FIP1L1 protein, human
  • Oncogene Proteins, Fusion
  • Piperazines
  • Pyrimidines
  • mRNA Cleavage and Polyadenylation Factors
  • Imatinib Mesylate
  • Receptor, Platelet-Derived Growth Factor alpha